Mr. Kapur is a deeply experienced executive with over 25 years of experience in pharmaceutical and biotech companies across U.S. and international markets. He has held senior leadership positions where he has been responsible for launching significant global brands, building and managing commercial capabilities in small and large organizations, driving corporate strategy, and managing alliances.
 

Mr. Kapur is currently a member of the Board of Directors for Nurix Therapeutics. Most recently, he served as the Executive Vice President, Corporate Strategy and Chief Commercial Officer at Geron Corporation. Before Geron, Mr. Kapur served as the Chief Commercial Officer at Actinium Pharmaceuticals, Inc. and as the Vice President, Head of Early Assets, Biomarkers and External Innovation for Worldwide Oncology Commercialization at Bristol-Myers Squibb. Previously, Mr. Kapur was Vice President, Global Head of Commercial and Portfolio Strategy at Baxalta, Inc., which was acquired by Shire PLC in 2016. Before joining Baxalta, Mr. Kapur served as the Vice President, Commercial Leader Hematology Franchise at Johnson & Johnson’s global pharmaceutical strategy organization and in various sales and marketing leadership roles.
 

Mr. Kapur holds a Bachelor of Engineering from Birla Institute of Technology in India, a Master of Science in Industrial Engineering from Louisiana Tech University, and a Master of Business Administration from the Fuqua School of Business at Duke University.